Bloomberg with the report
Most Popular
Sponsored
ENR's 16.3% rally faces flat revenue forecasts. Peers surge, but ENR's valuation at $19.60 vs $21 target hints caution.
Medicare costs rise unpredictably, unlike Social Security. Plan for higher premiums & deductibles.
Cerebras eyes $26.6B valuation in IPO, pricing shares $115-$125 amid AI chip boom.
NSSC revenue in line, but EPS misses. Adjusted EBITDA beats, margins mixed. Stock up 6%.
CVX up 25% YTD on Mideast conflict & Iraq oil fields. Huge reserves found, but long-term impact uncertain.
CRC faces earnings pressure; revenue down 13.8% YoY. Analysts eye 6% growth, but past misses loom. Buy target $81.17 vs $68.37.
Oil prices jumped 5% on Iran missile claims, then eased. WTI & Brent saw gains amid Strait of Hormuz tensions.
Sponsored
Must Read
